Allergy Therapeutics has announced findings from the mEEC dose-ranging study G204 from the US GrassMATAMPL clinical development programme. Further dose range finding will be required in order to optimise the recommended dose before starting the pivotal Phase III trial (G306). While we anticipate this will potentially add circa 12 months to the development road-map, the nowexpected absence of a high-profile peer in the future US marketplace – Circassia – combined with accelerating
